Environmental exposure to DON and its possible role in Crohn's disease
Official title: dEoxyniValenol as Risk Factor for Inflammatory Bowel Diseases: Human detoxifiCaTion and Impact On intestiNal Microbiota and Homeostasis
Run by University Hospital, Lille · NCT04960826 · Data updated 2026-11-12
This study will test whether exposure to the food contaminant DON affects gut exposure, metabolism, and harm in people with ileocolic Crohn's disease compared with people having similar bowel surgery for other reasons.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 25 Years to 60 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Hospital, Lille Academic / other |
| Locations | 1 site (Lille) |
| Status | Recruiting |
| Started | September 27, 2021 |
| Main results expected | July 2026 |
| Study ends | July 2026 |
| Registry record updated | December 26, 2025 |
| Trial ID | NCT04960826 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults scheduled for ileal and/or colonic surgery who have ileocolic Crohn's disease or are undergoing similar surgery for non-IBD reasons, who do not follow restrictive diets, have no prior intestinal resection, and have not taken antibiotics, probiotics, or topical 5-ASA/corticosteroids in the past six weeks.
✕Probably not a fit
People not undergoing the specified surgery, or those with celiac disease, gluten sensitivity, vegetarian/vegan diets, recent antibiotic/probiotic or topical IBD treatments, prior intestinal resections, or ulcerative colitis are unlikely to be eligible or to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational study focused on the human relevance of DON (deoxynivalenol) gut effects by measuring exposure, metabolism, and adverse effects in people with ileocolic Crohn's disease and in control patients undergoing ileal and/or colonic surgery for non-IBD reasons. Participants are grouped into Crohn's patients requiring surgery and non-IBD surgical controls to allow comparison of DON-related markers. Key exclusions include vegetarian/vegan diets, celiac disease or gluten sensitivity, prior intestinal resection, and recent antibiotic, probiotic, or topical 5-ASA/corticosteroid use. Data will be collected around the time of surgery to characterize DON exposure and its gut effects in health and disease.
Why it matters
Potential benefit: If a link between DON exposure and Crohn's-related gut changes is found, patients could receive practical guidance to reduce exposure and inform prevention strategies.
How similar studies have gone: Animal and laboratory studies suggest DON can affect the gut, but human data on DON as a Crohn's risk factor are limited, so this human-focused approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Group 1: patients with ileocolic Crohn's disease requiring surgery * Group 2: Patients requiring ileal and / or colonic surgery for a reason other than Crohn's disease or ulcerative colitis (for example, cancer, polyp or diverticulum). Exclusion Criteria: * Vegetarian or vegan patients, celiac disease, gluten sensitivity, eating disorders, people with a particular diet or eating behavior or suffering from obesity or anorexia * Surgical history: patient having undergone intestinal resection * Current treatments: patient receiving antibiotic or probiotic treatment within 6 weeks prior to inclusion / patient having taken topical treatment (suppositories or enema of 5ASA or corticosteroids) within 6 weeks prior to inclusion
Where it's running
-
Lille University Hospital
Lille, France Recruiting
Study contacts
- Principal investigator: Philippe ZERBIB, MD,PhD — University Hospital, Lille
- Study coordinator: Philippe ZERBIB, MD,PhD
- Email: philippe.zerbib@chru-lille.fr
- Phone: 0320445962
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Long-Term Guselkumab Use in Adults with Inflammatory Bowel Disease
This study looks at how long adults with Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.
-
Intestinal ultrasound-guided management for inflammatory bowel disease
This study tests if adding point-of-care intestinal ultrasound at every visit changes treatment decisions for adults with Crohn’s disease or ulcerative colitis undergoing disease assessment.
-
Resting energy use in kids with inflammatory bowel disease
This multicenter study will test the resting energy expenditure of children aged 6–17 with new IBD diagnoses to see how it relates to disease activity and treatment.
-
Active video education by disease subtype to improve bowel prep before colonoscopy
We’re testing whether adding subtype-specific video education to standard prep improves bowel cleanliness in adults with IBD undergoing colonoscopy.
-
Intestinal ultrasound to predict relapse in Crohn's disease patients in deep remission.
This project will try to see if a noninvasive transabdominal ultrasound can predict relapses in adults with Crohn's disease who are currently in deep remission.
-
Ath-063: Testing a new treatment for moderately to severely active ulcerative colitis in patients who have tried other biologics
This study tests ATH-063 to see if it helps people with moderate to severe ulcerative colitis who did not respond to or relapsed after prior biologic therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.